Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation
- 1 October 1998
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 352 (9134) , 1087-1092
- https://doi.org/10.1016/s0140-6736(98)03030-x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationBone Marrow Transplantation, 1997
- Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 1997
- Blood and marrow transplantation activity in Europe 1995Bone Marrow Transplantation, 1997
- Chronic myelogenous leukemia: A reviewThe American Journal of Medicine, 1996
- Bone Marrow TransplantationNew England Journal of Medicine, 1994
- Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid LeukemiaNew England Journal of Medicine, 1994
- Treatment of chronic myeloid leukemia by marrow transplantation [editorial; comment] [see comments]Blood, 1993
- Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous LeukemiaAnnals of Internal Medicine, 1991
- ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIAThe Lancet, 1984
- Disappearance of pH1-Positive Cells in Four Patients with Chronic Granulocytic Leukemia after Chemotherapy, Irradiation and Marrow Transplantation from an Identical TwinNew England Journal of Medicine, 1979